Lateral Epicondylitis Treatment Global Market Report 2025

The lateral epicondylitis treatment market size has grown strongly in recent years. It will grow from $2.22 billion in 2024 to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be attributed to several factors, including the rising prevalence of lateral epicondylitis, an aging population increasingly susceptible to musculoskeletal disorders, a higher incidence of the condition among athletes and manual laborers, greater awareness of repetitive strain injuries, and the impact of sedentary urban lifestyles that contribute to joint and muscle strain.

The lateral epicondylitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to the increasing number of tennis and racquet sports players, a rise in occupational hazards in sectors like construction and manufacturing, higher disposable incomes facilitating better access to treatment, the expansion of physical therapy and orthopedic clinic networks, and the growing significance of sports medicine departments. Key trends expected during this period include innovations in non-invasive treatment methods, advancements in regenerative medicine, the development of robotic-assisted physiotherapy, the growing use of wearable rehabilitation devices, and the integration of AI-assisted diagnostics and personalized treatment approaches.

The increasing participation in sports and physical activities is expected to drive growth in the lateral epicondylitis treatment market. Sports and physical activities encompass both structured and recreational movements aimed at improving fitness, maintaining health, or engaging in competitive or leisure pursuits. This rise in activity is largely driven by growing health awareness, as more individuals prioritize physical fitness to prevent illness and enhance overall well-being. Lateral epicondylitis treatment supports these activities by restoring pain-free arm function, enabling actions such as gripping and swinging without discomfort. For example, in February 2024, the Sports and Fitness Industry Association (SFIA), a US-based trade association, reported that 78.8% of Americans - or 242 million people - engaged in at least one physical activity in 2023, marking a 2.2% increase from the previous year. Thus, the rising engagement in sports and physical activities is fueling the demand for lateral epicondylitis treatment.

Major companies in the lateral epicondylitis treatment market are increasingly focusing on innovative therapies, such as plasma-based treatments, to expand non-surgical options for orthopedic conditions. Plasma therapies utilize components of blood plasma - especially growth factors or antibodies - to accelerate healing and support tissue regeneration. For example, in December 2023, Tree Top Hospital (TTH), a Maldives-based advanced healthcare facility, introduced platelet-rich plasma (PRP) therapy as part of its orthopedic care offerings. This minimally invasive treatment targets musculoskeletal conditions including lateral epicondylitis (tennis elbow), early-stage knee arthritis, and sports-related tendon injuries. By incorporating PRP therapy, TTH aims to enhance recovery outcomes using the body’s natural healing mechanisms, reducing reliance on surgical procedures and offering patients an evidence-based, regenerative solution.

In March 2023, TendoNova, a US-based provider of lateral epicondylitis treatment solutions, partnered with AcCELLerated Biologics LLC to expand market reach and enhance clinical capabilities. This strategic collaboration aims to integrate TendoNova’s micro-invasive tendon treatment technologies with AcCELLerated Biologics’ biologic therapies, offering a comprehensive approach to managing chronic tendon disorders. By aligning device innovation with biologic solutions, the partnership seeks to broaden physician access and improve patient outcomes in the treatment of conditions such as lateral epicondylitis. AcCELLerated Biologics LLC is a US-based supplier of biologic products used in orthopedic and regenerative treatments.

Major players in the lateral epicondylitis treatment market are Merck & Co. Inc., 3M Company, Mayo Foundation for Medical Education and Research (MFMER), Cleveland Clinic, Chugai Pharmaceutical, Johns Hopkins Medicine, MedStar Health, Cipla Inc., Enovis Corporation, OttoBock HealthCare, Ossur Corporate, Max Healthcare, Seikagaku Corporation, Texas Orthopedic Specialists, Johari Digital, Mediheal Group of Hospitals, Scandinavian Physiotherapy Center, Veritas Health LLC, Folsom Orthopaedics & Sports Medicine, ReLiva Physiotherapy & Rehab, Molecular Pharmacology Limited.

North America was the largest region in the lateral epicondylitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lateral epicondylitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lateral epicondylitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lateral epicondylitis treatment encompasses various clinical interventions designed to alleviate pain, reduce inflammation, and promote healing in individuals affected by lateral epicondylitis - a condition resulting from overuse or strain of the forearm tendons. The goal of treatment is to restore normal arm function, improve mobility and strength, and facilitate a return to daily or occupational activities without symptom recurrence.

The primary treatment types include non-surgical and surgical options. Non-surgical treatments involve conservative approaches such as physical therapy, bracing, medications, and regenerative therapies like platelet-rich plasma (PRP) to manage symptoms and restore function without surgery. These treatments cater to different age groups, including pediatric, adult, and geriatric populations, and are applied in contexts such as athletic and general use. Treatment is delivered across various settings, including hospitals, ambulatory surgical centers, orthopedic clinics, homecare environments, and other healthcare facilities.

The lateral epicondylitis treatment market research report is one of a series of new reports that provides lateral epicondylitis treatment market statistics, including lateral epicondylitis treatment industry global market size, regional shares, competitors with a lateral epicondylitis treatment market share, detailed lateral epicondylitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lateral epicondylitis treatment industry. This lateral epicondylitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lateral epicondylitis treatment market consists of revenues earned by entities by providing services such as outpatient musculoskeletal physiotherapy sessions, telehealth consultations for elbow pain, occupational therapy programs, post-surgical recovery and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lateral epicondylitis treatment market also includes sales of platelet-rich plasma (PRP) kits, extracorporeal shock wave therapy (ESWT) devices, ultrasound therapy equipment, elbow support braces with biofeedback sensors, and topical anti-inflammatory gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.